Table 3.

Univariable and multivariable analyses of the influence of clinical parameters on OS in NSCLC patients with different sites of metastases receiving first-line ICIs monotherapy.

	Univariable analysis			Multivariable analysis†
Factor	HR	95% CI	P	HR	95% CI	P
Age (≥60 years/<60 years)	1.055	0.360–3.090	0.922
Sex (male/female)	0.579	0.184–1.820	0.350
Smoking (ever/never)	0.506	0.183–1.397	0.188
Pathology (squamous/non-squamous)	0.945	0.323–2.768	0.918
Liver metastasis (yes/no)	4.473	1.612–12.409	0.004	4.473	1.612–12.409	0.004
Bone metastasis (yes/no)	1.303	0.463–3.664	0.616
Brain metastasis (yes/no)∗	2.310	0.722–7.390	0.158

^∗Patients with brain metastasis who previously received local treatment were excluded.

^†Variables with P < 0.20 in univariable analysis were taken forward for consideration in the multivariable analysis, and multivariable analysis was conducted using the forward stepwise regression method. CI: Confidence interval; HR: Hazard ratio; ICIs: Immune checkpoint inhibitors; NSCLC: Non-small-cell lung cancer; OS: Overall survival.